Search Results - daniel+labarbera

2 Results

Sort By:

Drugs That Reverse Epithelial-Mesenchymal Transition For The Treatment Of Metastatic Cancers

Epithelial-mesenchymal transition (EMT) is a driving force in tumor progression that transforms relatively benign epithelial tumor cells into mesenchymal or quasi-mesenchymal cells with cancer stem cell (CSC) properties, promoting the malignant phenotype that is highly drug resistant and metastatic. University of Colorado researchers have discovered...

Published: 11/30/2023 | Inventor(s): Daniel LaBarbera, Qiong Zhou, Adedoyin Abraham

Disease Areas Oncology

Category(s): Therapeutics

Novel anti-metastatic agents that reverse epithelial-mesenchymal transition (EMT) in cancer (CHD1L).

Colorectal cancer (CRC) is one of the most prevalent forms of cancer with over 150,000 new cases reported each year. Stage 4 CRC patients have very poor survival rates at only 11% and there are currently no effective therapeutics for treating metastatic CRC. The epithelial-mesenchymal transition (EMT) is a driving force for tumor progression, tumor...

Published: 12/1/2023 | Inventor(s): Daniel LaBarbera, Qiong Zhou, Joshua Abbott, Hector Esquer, Brett Prigaro

Disease Areas Oncology

Category(s): Therapeutics